TW200503691A - Therapeutic agents - Google Patents

Therapeutic agents

Info

Publication number
TW200503691A
TW200503691A TW093119064A TW93119064A TW200503691A TW 200503691 A TW200503691 A TW 200503691A TW 093119064 A TW093119064 A TW 093119064A TW 93119064 A TW93119064 A TW 93119064A TW 200503691 A TW200503691 A TW 200503691A
Authority
TW
Taiwan
Prior art keywords
compounds
therapeutic agents
aizheimer
nr1h2
nr1h3
Prior art date
Application number
TW093119064A
Other languages
English (en)
Inventor
Kay Brickmann
Patrik Holm
Pernilla Sandberg
Marianne Swanson
Christer Westerlund
Jonas Bostrom
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW200503691A publication Critical patent/TW200503691A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW093119064A 2003-07-11 2004-06-29 Therapeutic agents TW200503691A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0316232.8A GB0316232D0 (en) 2003-07-11 2003-07-11 Therapeutic agents

Publications (1)

Publication Number Publication Date
TW200503691A true TW200503691A (en) 2005-02-01

Family

ID=27741983

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093119064A TW200503691A (en) 2003-07-11 2004-06-29 Therapeutic agents

Country Status (26)

Country Link
US (1) US7432288B2 (zh)
EP (1) EP1646626B1 (zh)
JP (1) JP2007521312A (zh)
KR (1) KR20060035748A (zh)
CN (1) CN1823061A (zh)
AR (1) AR045721A1 (zh)
AT (1) ATE399777T1 (zh)
AU (1) AU2004255999B2 (zh)
BR (1) BRPI0412472A (zh)
CA (1) CA2532056A1 (zh)
DE (1) DE602004014773D1 (zh)
ES (1) ES2308204T3 (zh)
GB (1) GB0316232D0 (zh)
HK (1) HK1088320A1 (zh)
IL (1) IL172760A0 (zh)
IS (1) IS8293A (zh)
MX (1) MXPA06000414A (zh)
MY (1) MY135821A (zh)
NO (1) NO20060081L (zh)
RU (1) RU2006102130A (zh)
SA (1) SA04250204B1 (zh)
TW (1) TW200503691A (zh)
UA (1) UA82109C2 (zh)
UY (1) UY28408A1 (zh)
WO (1) WO2005005417A1 (zh)
ZA (1) ZA200600222B (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE513823T1 (de) * 2004-08-17 2011-07-15 Simpson Biotech Co Ltd Mischung und verbindungen von mycelien von antrodia camphorata und deren verwendung
US7505238B2 (en) * 2005-01-07 2009-03-17 Agnes Neves Woo ESD configuration for low parasitic capacitance I/O
CA2592771A1 (en) 2005-01-10 2006-07-13 Astrazeneca Ab Derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
US8299113B2 (en) * 2006-04-28 2012-10-30 Laboratorios Del Dr. Esteve, S.A. Bicyclic tetrahydropyrrole compounds
KR101475088B1 (ko) 2006-08-21 2014-12-23 제넨테크, 인크. 아자-벤조티오페닐 화합물 및 사용 방법
CN101456863B (zh) * 2007-12-14 2012-04-25 华北制药集团新药研究开发有限责任公司 Lxr激动剂及其制备方法和用途
US8841462B2 (en) 2008-07-01 2014-09-23 Robert A. Heald Bicyclic heterocycles as MEK kinase inhibitors
PE20110424A1 (es) 2008-07-01 2011-07-22 Genentech Inc Isoindolonas que inhiben la cinasa mek
AU2011299703A1 (en) 2010-09-07 2013-04-11 Snu R&Db Foundation Sesterterpene compounds and use thereof
KR20130127479A (ko) 2010-12-03 2013-11-22 알러간, 인코포레이티드 스핑고신 1-포스페이트 (s1p) 수용체 조절제로서의 신규한 옥심 유도체
RU2013129747A (ru) 2010-12-03 2015-01-10 Аллерган, Инк. Новые оксимовые производные азетидина в качестве модуляторов рецептора сфингозин 1-фосфата (s1p)
EP3091970B1 (en) 2014-01-10 2020-10-28 Rgenix, Inc. Lxr agonists and uses thereof
EP3402477A4 (en) 2016-01-11 2019-08-21 The Rockefeller University METHODS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH SUPPRESSIVE CELLS DERIVED FROM MYELOID CELLS
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
CN114728875A (zh) 2019-12-13 2022-07-08 因思博纳公司 金属盐及其用途
WO2022109066A1 (en) * 2020-11-18 2022-05-27 Southern Research Institute Compounds for the treatment of acute and chronic kidney disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1120414A1 (en) 1998-07-30 2001-08-01 Japan Tobacco Inc. Disubstituted maleimide compounds and medicinal utilization thereof
DE69922526T2 (de) * 1998-10-08 2005-06-02 Smithkline Beecham Plc, Brentford 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
EP1212065A4 (en) 1999-07-08 2004-02-11 Tularik Inc COMPILATIONS AND METHODS FOR INCREASING THE HDL CHOLESTEROL LEVEL
AU6593600A (en) 1999-08-20 2001-03-19 Rei Asakai Drugs inhibiting cell death
GB0008264D0 (en) 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds

Also Published As

Publication number Publication date
BRPI0412472A (pt) 2006-09-19
WO2005005417A1 (en) 2005-01-20
EP1646626A1 (en) 2006-04-19
UA82109C2 (uk) 2008-03-11
IL172760A0 (en) 2006-04-10
ES2308204T3 (es) 2008-12-01
HK1088320A1 (en) 2006-11-03
UY28408A1 (es) 2005-02-28
AU2004255999A1 (en) 2005-01-20
SA04250204B1 (ar) 2008-03-23
AU2004255999B2 (en) 2007-08-02
CA2532056A1 (en) 2005-01-20
IS8293A (is) 2006-02-09
EP1646626B1 (en) 2008-07-02
US7432288B2 (en) 2008-10-07
JP2007521312A (ja) 2007-08-02
RU2006102130A (ru) 2007-08-20
CN1823061A (zh) 2006-08-23
AR045721A1 (es) 2005-11-09
ZA200600222B (en) 2007-04-25
ATE399777T1 (de) 2008-07-15
NO20060081L (no) 2006-02-08
MY135821A (en) 2008-07-31
US20060235015A1 (en) 2006-10-19
GB0316232D0 (en) 2003-08-13
MXPA06000414A (es) 2006-03-17
DE602004014773D1 (de) 2008-08-14
KR20060035748A (ko) 2006-04-26

Similar Documents

Publication Publication Date Title
SE0500055D0 (sv) Therapeutic agents 3
TW200507836A (en) Therapeutic agents
TW200503691A (en) Therapeutic agents
TW200503674A (en) Therapeutic agents
RU2003114748A (ru) Новые соединения, не являющиеся имидазолами
TWI255807B (en) Therapeutic agents
SE0500056D0 (sv) Therapeutic agents 4
TW200508180A (en) Therapeutic agents
CA2597069A1 (en) Pyridazine derivatives and their use as therapeutic agents
ATE268179T1 (de) Verwendung von substituierten imidazo (1,2- a)pyridin-, -pyrimidin- und -pyrazin-3-yl-amin- derivaten zur herstellung von medikamenten zur nos-inhibierung
BR0113251A (pt) Compostos, composição cosmética, composição farmacêutica, uso cosmético de uma composição e uso de um composto
MY135920A (en) New phenalkyloxy-phenyl derivatives
BR0314898A (pt) Compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica
SE0500058D0 (sv) Therapeutic agents 5
HK1079526A1 (en) A novel pyrazine compound and its use in the manufacture of a medicament for treating diseases related to serotonin
NZ516290A (en) Substituted phenoxyacetic acids
SE9904421D0 (sv) New compounds
HK1058190A1 (en) Novel heterocyclic analogs of diphenylethylene compounds
BRPI0606388A2 (pt) composto, processo para a preparação do mesmo, formulação farmacêutica, e, uso de um composto
MXPA03011004A (es) Derivados de fenilalquiloxi-fenilo novedosos.
SE0500054D0 (sv) Therapeutic agents 2
MY143584A (en) Non-anilinic derivatives of isothiazol-3(2h)-one 1, 1-dioxides as liver x receptor modulators
TW200724138A (en) Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use
BR0315951A (pt) Compostos, composição cosmética, uso cosmético de uma composição, uso de um composto e composição farmacêutica
TW200503999A (en) Therapeutic agents